Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fasting Duration and Withholding GLP-1 RAs on Gastric Contents
NCT07225816Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of liraglutide and semaglutide in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Occurrence of empty stomach (antrum grade 0 or 1) at 24 hours. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07225816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225816.